Calyx Supply Simulation Service Launched
Service uses simulation modeling methodology to evaluate the quantity of medication produced for use in clinical development.
E-Clinical and Regulatory solutions and services provider Calyx has announced its Calyx Supply Simulation clinical trial supply forecasting service. Available through the company’s in-house statistical design and trial supplies consultants, the service uses simulation modeling methodology and over 50 design parameters that closely mimic an Interactive Response Technology (IRT) system, to evaluate the quantity of medication produced for use in clinical development.
By providing better-aligned medication scenarios—for trial start-up and continued enrollment, how long an existing amount of study medication will last and determining optimal site and depot buffer stock quantities—can help sponsors reduce cost and excessive drug wastage.
Reference: Calyx Launches Supply Simulation Service to Forecast and Optimize Clinical Trial Supplies; Nottingham, England and Morrisville, NC. March 7, 2023
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
